Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Go back to Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile| Isilon Systems, Inc. (NASDAQ: SLN) | Delayed: 12.20 -0.5 (3.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.70 | 52 Week High | $0.27 | |||
| Open | $12.59 | 52 Week Low | $0.18 | |||
| Day High | $12.74 | P/E | N/A | |||
| Day Low | $12.14 | EPS | $-0.44 | |||
| Volume | 1,142,412 | |||||
